VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Schnabel Discusses the DCIS Recurrence Score

Freya R. Schnabel, MD
Published: Friday, Mar 09, 2012

Freya R. Schnabel, MD, Professor of Surgery, NYU School of Medicine, discusses ability to predict the risk for recurrence in women with ductal carcinoma in situ (DCIS) using a new 12-gene assay named the DCIS Score.

The study that examined the DCIS Score was designed to explore the tumor samples of women who had received surgery alone without radiation. This analysis found a panel of genes that could help predict whether the patient was at low-, intermediate-, or high-risk for recurrence.

Determining the recurrence risk at the time of lumpectomy aids future treatment decisions, including whether or not to use radiation therapy. Schnabel labels the ability to predict risk a major advance.

Freya R. Schnabel, MD, Professor of Surgery, NYU School of Medicine, discusses ability to predict the risk for recurrence in women with ductal carcinoma in situ (DCIS) using a new 12-gene assay named the DCIS Score.

The study that examined the DCIS Score was designed to explore the tumor samples of women who had received surgery alone without radiation. This analysis found a panel of genes that could help predict whether the patient was at low-, intermediate-, or high-risk for recurrence.

Determining the recurrence risk at the time of lumpectomy aids future treatment decisions, including whether or not to use radiation therapy. Schnabel labels the ability to predict risk a major advance.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x